Complete financial analysis of NuGen Medical Devices Inc. (NGMDF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NuGen Medical Devices Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Public Joint Stock Company Gazprom (GAZ.DE) Income Statement Analysis – Financial Results
- Sagalio Energy Limited (SAN.AX) Income Statement Analysis – Financial Results
- Hikari Tsushin, Inc. (HKTGF) Income Statement Analysis – Financial Results
- Midatech Pharma plc (MTP) Income Statement Analysis – Financial Results
- Prodigy Public Company Limited (PDG.BK) Income Statement Analysis – Financial Results
NuGen Medical Devices Inc. (NGMDF)
About NuGen Medical Devices Inc.
NuGen Medical Devices Inc., a specialty medical device company, focuses on developing and commercializing novel drug delivery technologies. It offers needle-free injection devices and systems for the administration of subcutaneous medication for various fields, including anaphylaxis, diabetes, severe migraine, erectile dysfunction, chronic anemia, neutropenia, autoimmune rheumatoid arthritis, growth and fertility hormone, and psoriasis, as well as DNA and conventional/pediatric vaccines. The company was formerly known as BuzBuz Capital Corp. NuGen Medical Devices Inc. is based in Toronto, Canada.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
---|---|---|---|---|---|---|---|
Revenue | 331.40K | 152.36K | 137.65K | 47.30K | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 166.56K | 705.59K | 45.42K | 12.91K | 0.00 | 0.00 | 0.00 |
Gross Profit | 164.84K | -553.23K | 92.22K | 34.39K | 0.00 | 0.00 | 0.00 |
Gross Profit Ratio | 49.74% | -363.11% | 67.00% | 72.70% | 0.00% | 0.00% | 0.00% |
Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 7.52M | 4.24M | 1.72M | 0.00 | 995.65K | 603.33K | 415.77K |
Selling & Marketing | 0.00 | 0.00 | 6.05M | 2.65M | 478.44K | 582.57K | 98.78K |
SG&A | 7.52M | 4.24M | 7.76M | 2.65M | 132.14K | 1.66M | 608.03K |
Other Expenses | 690.84K | 57.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 8.21M | 4.24M | 7.76M | 2.65M | 132.14K | 1.65M | 610.57K |
Cost & Expenses | 8.38M | 4.95M | 7.81M | 2.66M | 132.14K | 1.65M | 610.57K |
Interest Income | 0.00 | 150.91K | 20.00K | 22.85K | 0.00 | 136.87K | 104.42K |
Interest Expense | 1.24M | 1.01M | 1.22M | 672.19K | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 690.84K | 652.40K | 626.94K | 387.78K | 1.20K | 1.29K | 1.76K |
EBITDA | -7.40M | -4.14M | -5.17M | -2.22M | -132.14K | -1.66M | -608.03K |
EBITDA Ratio | -2,233.32% | -2,718.36% | -4,979.77% | -5,135.51% | 0.00% | 0.00% | 0.00% |
Operating Income | -8.05M | -4.79M | -7.67M | -2.61M | -132.14K | -1.66M | -609.79K |
Operating Income Ratio | -2,428.48% | -3,146.56% | -5,573.13% | -5,521.05% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | -1.28M | -780.71K | -1.31M | -1.05M | -24.20K | -129.70K | -105.20K |
Income Before Tax | -9.33M | -5.57M | -7.10M | -3.66M | -156.34K | -1.79M | -714.98K |
Income Before Tax Ratio | -2,814.83% | -3,658.98% | -5,161.08% | -7,734.93% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 33.80K | 3.18K | 2.96K | 12.17K | -1.20K | 0.00 | 0.00 |
Net Income | -9.36M | -5.58M | -7.11M | -3.67M | -156.34K | -1.79M | -714.98K |
Net Income Ratio | -2,825.02% | -3,661.07% | -5,163.23% | -7,760.66% | 0.00% | 0.00% | 0.00% |
EPS | -0.06 | -0.06 | -0.10 | -0.14 | -0.03 | -0.09 | -0.07 |
EPS Diluted | -0.06 | -0.06 | -0.10 | -0.14 | -0.03 | -0.09 | -0.07 |
Weighted Avg Shares Out | 167.66M | 90.10M | 68.67M | 27.05M | 4.75M | 19.65M | 9.70M |
Weighted Avg Shares Out (Dil) | 167.66M | 90.10M | 68.67M | 27.05M | 4.75M | 19.65M | 9.70M |
NuGen Announces Canada-Wide Launch of InsuJet
NuGen Announces Results of Special Meeting and Appointment of New Directors
NuGen Announces Strategic Partnership with EziAutoJector Limited
NuGen Announces Closing of Private Placement of $10 million Secured Convertible Debentures
NuGen Announces Release of Financial Results for Q2 2024 & Update on Proposed Private Placement
NuGen Announces Voting Results of Annual and Special Meeting
NuGen Announces Revised Terms of Proposed Private Placement of up to $10 Million Secured Convertible Debentures
NuGen Receives Order for Repeat Demand in Mexico
NuGen Announces Proposed Private Placement of up to $10 million Secured Convertible Debentures
NuGen Develops Pharmacist Training Packages for the Canadian Retail Pharmacy Market
Source: https://incomestatements.info
Category: Stock Reports